Literature DB >> 8619594

NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species.

S Chokekijchai1, E Kojima, S Anderson, M Nomizu, M Tanaka, M Machida, T Date, K Toyota, S Ishida, K Watanabe.   

Abstract

From an extract of a Streptomyces culture, we identified and purified a novel compound, NP-06, which is active against human immunodeficiency virus (HIV) in vitro. Analyses indicate that NP-06 is a hydrophobic 21-mer oligopeptide, N terminally cyclized through the side chain of Asp-9, containing two intramolecular cystine linkages with a molecular weight of 2,163.4. The 50% inhibitory concentrations were 2.8 and 1.3 microM when NP-06 was tested for in vitro anti-HIV-1 activity in ATH8 cells and phytohemagglutinin-activated peripheral blood mononuclear cells, respectively, NP-06 appears to block the early stage of HIV-1 infection, most likely at the stage of virus-cell fusion.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8619594      PMCID： PMC162941          DOI： 10.1128/AAC.39.10.2345

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

2.  Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus.

Authors:  D Fréchet; J D Guitton; F Herman; D Faucher; G Helynck; B Monegier du Sorbier; J P Ridoux; E James-Surcouf; M Vuilhorgne
Journal:  Biochemistry       Date:  1994-01-11       Impact factor: 3.162

3.  A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.

Authors:  H Tamamura; M Kuroda; M Masuda; A Otaka; S Funakoshi; H Nakashima; N Yamamoto; M Waki; A Matsumoto; J M Lancelin
Journal:  Biochim Biophys Acta       Date:  1993-05-13

4.  Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.

Authors:  H Nakashima; M Masuda; T Murakami; Y Koyanagi; A Matsumoto; N Fujii; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

5.  Inhibitors of human immunodeficiency virus integrase.

Authors:  M R Fesen; K W Kohn; F Leteurtre; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

6.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

7.  A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).

Authors:  M Masuda; H Nakashima; T Ueda; H Naba; R Ikoma; A Otaka; Y Terakawa; H Tamamura; T Ibuka; T Murakami
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

8.  Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.

Authors:  E T Baldwin; T N Bhat; S Gulnik; B Liu; I A Topol; Y Kiso; T Mimoto; H Mitsuya; J W Erickson
Journal:  Structure       Date:  1995-06-15       Impact factor: 5.006

9.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.

Authors:  M Baba; S Shigeta; S Yuasa; H Takashima; K Sekiya; M Ubasawa; H Tanaka; T Miyasaka; R T Walker; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191
  10 in total
  6 in total

1.  Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain.

Authors:  Hua Xie; Natalya I Belogortseva; Jie Wu; Wei-Hong Lai; Chin-ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  How to harness biosynthetic gene clusters of lasso peptides.

Authors:  Shinya Kodani; Kohta Unno
Journal:  J Ind Microbiol Biotechnol       Date:  2020-07-23       Impact factor: 3.346

3.  Siamycin attenuates fsr quorum sensing mediated by a gelatinase biosynthesis-activating pheromone in Enterococcus faecalis.

Authors:  Jiro Nakayama; Emi Tanaka; Reiko Kariyama; Koji Nagata; Kenzo Nishiguchi; Ritsuko Mitsuhata; Yumi Uemura; Masaru Tanokura; Hiromi Kumon; Kenji Sonomoto
Journal:  J Bacteriol       Date:  2006-10-27       Impact factor: 3.490

Review 4.  Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds.

Authors:  John A McIntosh; Mohamed S Donia; Eric W Schmidt
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

Review 5.  Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs).

Authors:  Yuxin Fu; Ate H Jaarsma; Oscar P Kuipers
Journal:  Cell Mol Life Sci       Date:  2021-02-02       Impact factor: 9.261

6.  Structure-Activity Analysis of Gram-positive Bacterium-producing Lasso Peptides with Anti-mycobacterial Activity.

Authors:  Junji Inokoshi; Nobuhiro Koyama; Midori Miyake; Yuji Shimizu; Hiroshi Tomoda
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.